You are here

Senseion Therapeutics, Inc.

Company Information
Address
7241 Forsyth Blvd
Saint Louis, MO 63105-2116
United States



Information

UEI: V2KQH21BGKY5

# of Employees: 2


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Targeting LRRC8 signaling to prevent and treat arterial thrombosis in type 2 diabetes

    Amount: $323,485.00

    Project SummaryCardiovascular disease (CVD) including stroke and myocardial infarction (MI), and Type 2 diabetes (T2D) areoverlapping global pandemics. CVD is the most common cause of death in patient ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis

    Amount: $2,035,065.00

    Non-alcoholic fatty liver (NAFL) and its progression to advanced stage non-alcoholic steatohepatitis (NASH) is a growing health concern, with 83.1 million Americans affected in 2015, and projections t ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  3. Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes

    Amount: $1,984,107.00

    Project Summary/Abstract More than 100 million Americans currently have diabetes or pre-diabetes, a condition that can lead to Type 2 diabetes (T2D) within five years, and that vastly increases advers ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  4. Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis

    Amount: $301,025.00

    Non-alcoholic fatty liver (NAFL) and its progression to advanced stage non-alcoholic steatohepatitis (NASH) is a growing health concern, with 83.1 million Americans affected in 2015, and projections t ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government